ProMIS Neurosciences Inc (PMN)
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
📈 **POSITIVE** • Medium confidence analysis (63%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (76%) **Content type:** Clinical